<DOC>
	<DOCNO>NCT01717300</DOCNO>
	<brief_summary>This study evaluate effect 2 different dose level anacetrapib low-density lipoprotein-cholesterol ( LDL-C ) high-density lipoprotein cholesterol ( HDL-C ) participant hypercholesterolemia add exist statin-modifying therapy .</brief_summary>
	<brief_title>A Study Safety Efficacy Anacetrapib ( MK-0859 ) When Added Ongoing Statin Therapy ( MK-0859-021 )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Anacetrapib</mesh_term>
	<mesh_term>Oxazolidinones</mesh_term>
	<criteria>If female , reproductive potential Have treat optimal dose statin least 6 week Coronary heart disease ( CHD ) atherosclerotic vascular disease multiple risk factor ( include diabetes , metabolic syndrome ) and/or high LDLC/low HDLC , need meet specific LDLC/HDLC goal Previously participate study cholesteryl ester transfer protein ( CETP ) inhibitor Homozygous familial hypercholesterolemia Severe chronic heart failure Uncontrolled cardiac arrhythmia , myocardial infarction ( MI ) , percutaneous coronary intervention ( PCI ) , coronary artery bypass graft ( CABG ) , unstable angina , stroke within 3 month Uncontrolled hypertension Uncontrolled endocrine metabolic disease know influence serum lipid lipoproteins Active chronic hepatobiliary , hepatic , gall bladder disease History mental instability , drug/alcohol abuse within past five year major psychiatric illness inadequately control unstable History ileal bypass , gastric bypass , significant condition associate malabsorption Human immunodeficiency virus ( HIV ) positive History malignancy â‰¤5 year Donated blood product phlebotomy &gt; 300 mL within 8 week intend donate 250 mL blood product receive blood product within project duration study Currently take medication potent inhibitor inducer cytochrome P450 3A4 ( CYP3A ) ( include limit cyclosporine , systemic itraconazole ketoconazole , erythromycin , clarithromycin , telithromycin , nefazodone , protease inhibitor , carbamazepine , phenobarbital , phenytoin , rifabutin , rifampin , St John 's wort ) discontinue treatment &lt; 3 week prior Consumes 2 alcoholic drink per day Currently participate participate study investigational compound device within 3 month Receiving treatment systemic corticosteroid take systemic anabolic agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>